论文部分内容阅读
反应停(酞咪哌啶酮)在经历了一场大起伏后,近年来再度引起临床学家的兴趣。由于它对许多难治的疾病如:Ⅱ型麻风反应、光敏性皮肤病、结节性痒疹红斑狼疮、复发性口疮、复发坏死性粘液腺周围炎、白塞氏病以及多形红斑、脂膜炎、异位性皮炎及溃疡性结肠炎等有效,而显示出新的应用价值,并预示可能有更广泛的前途。但是,作为老药新用,反应停现代治疗学的药理基础还不甚清楚;其化学本质、致畸和致神经炎的毒理学特征并未改变。因此,存在着正确认识、重新估价和进一步研究的问题。现将反应停的药理和毒理资料综述于下。
Response to stop (thalidomidone) after a great ups and downs, in recent years once again aroused the interest of clinicians. Because of its many refractory diseases such as: type II leprosy reaction, photosensitive skin disease, nodular prurigo lupus, recurrent aphthous, recurrent necrotizing mucinous glandular inflammation, Behcet’s disease and erythema multiforme, lipid membrane Inflammation, atopic dermatitis and ulcerative colitis and so on, showing a new application value, and indicates that there may be a broader future. However, the pharmacological basis of modern therapy as a new drug is not yet clear; the toxicological characteristics of its chemical nature, teratogenicity and neuritis have not changed. Therefore, there are issues of correct understanding, re-evaluation and further research. Now stop the reaction pharmacological and toxicological data summarized in the next.